116572-46-4

Basic information

• Product Name: Acetamide, N-(5-chloro-2,3-dihydro-3-oxo-2-phenyl-4-pyridazinyl)-
• CAS NO: 116572-46-4
• Molecular Formula: C12H10ClN3O2
• Molecular Weight: 263.683
• Mol File: 116572-46-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Acetamide, N-(5-chloro-2,3-dihydro-3-oxo-2-phenyl-4-pyridazinyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetamide, N-(5-chloro-2,3-dihydro-3-oxo-2-phenyl-4-pyridazinyl)-(116572-46-4)
• EPA Substance Registry System: Acetamide, N-(5-chloro-2,3-dihydro-3-oxo-2-phenyl-4-pyridazinyl)-(116572-46-4)

Safety Data

• Hazardous Substances Data: 116572-46-4(Hazardous Substances Data)

Upstream product

• 123-75-1 pyrrolidine 
• 116538-67-1 SKI-187116 
• 110-89-4 piperidine 
• 110-91-8 morpholine 
• 1121-92-2 heptamethyleneimine 
• 111-49-9 hexamethylene imine 
• 110-96-3 diisobutylamine 
• 1698-61-9 5-chloro-4-amino-2-phenyl-3(2H)-pyridazinone 
• 75-36-5 acetyl chloride 
• 109-89-7 diethylamine 

Downstream Products

• 194016-04-1 N-(3-Oxo-2-phenyl-5-pyrrolidin-1-yl-2,3-dihydro-pyridazin-4-yl)-acetamide 
• 125291-73-8 N-(3-Oxo-2-phenyl-5-piperidin-1-yl-2,3-dihydro-pyridazin-4-yl)-acetamide 
• 125291-76-1 N-(5-Morpholin-4-yl-3-oxo-2-phenyl-2,3-dihydro-pyridazin-4-yl)-acetamide 
• 194016-06-3 N-(5-Azocan-1-yl-3-oxo-2-phenyl-2,3-dihydro-pyridazin-4-yl)-acetamide 
• 194016-05-2 N-(5-Azepan-1-yl-3-oxo-2-phenyl-2,3-dihydro-pyridazin-4-yl)-acetamide 
• 125291-75-0 N-(5-Diisobutylamino-3-oxo-2-phenyl-2,3-dihydro-pyridazin-4-yl)-acetamide 
• 125291-77-2 N-(5-Diethylamino-3-oxo-2-phenyl-2,3-dihydro-pyridazin-4-yl)-acetamide 
• 194016-09-6 4-Amino-5-diethylamino-2-phenyl-2H-pyridazin-3-one 
• 125291-72-7 N-(5-Dimethylamino-3-oxo-2-phenyl-2,3-dihydro-pyridazin-4-yl)-acetamide 
• 125291-68-1 N-(5-Dipropylamino-3-oxo-2-phenyl-2,3-dihydro-pyridazin-4-yl)-acetamide 
• 125291-70-5 N-[5-(Butyl-ethyl-amino)-3-oxo-2-phenyl-2,3-dihydro-pyridazin-4-yl]-acetamide 

Relevant articles and documents

Compounds for the Treatment of Neurodegeneration and Stroke

Compounds and related methods for synthesis, and the use of compounds for the treatment of neurodegenerative diseases are disclosed. Compounds are disclosed in connection with PARG and/or PARP inhibition. Therapeutic applications are relevant for preventing or inhibiting neurological cell death for a variety of neurodegenerative conditions including Parkinson's disease, ischemia, and stroke. Also disclosed is a high-throughput screen for identifying compounds capable of inhibiting PARG and/or PARP.